img
© Reuters. Ascendis Pharma revenues off 64% in Q2 Ascendis Pharma (ASND) Q2 results (€): Revenues: 0.4M (-63.6%); Operating Loss: (24.7M) (-66.9%); Net Loss: (30.7M); Loss Per Share: (0.94) (-77.4%); Quick Assets: 127.3M (-29.4%). No guidance given. Now read: Ascendis Pharma A/S (ASND) Presents At Wedbush PacGrow Healthcare Conference – Slideshow   source-investing.com
img

Sellers included Fidelity funds like Fidelity OTC Portfolio, which sold 1.62 million shares, or 43 percent of its position during the quarter, as well as funds managed by T. Rowe Price Group (O:TROW), including T. Rowe Price Growth Stock Fund (O:PRGFX), which sold 1.33 million shares during the quarter or 48 percent of its position, recent securities filings show.

1 2 6,100
It is main inner container footer text